Louis Chang, MD
Ophthalmology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 34
- 9 carriers
- Offices
- 3
Offices
3 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
34 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
34 of 34 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A91494 · Current
Licensed to practise in California · since 2013 · expires 2028-06-30 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,333,151
Medicare paid this office $2,333,151 for 660 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 186 | $1,315,157 | None |
| Injection, faricimab-svoa, 0.1 mg | 40 | $407,046 | None |
| Injection of drug into eye | 245 | $152,495 | $116 |
| Injection, ranibizumab, 0.1 mg | 33 | $129,261 | None |
| Imaging of retina | 612 | $92,106 | $41 |
See all 15 services
| Injection, aflibercept, 1 mg | 186 | $1,315,157 | None |
| Injection, faricimab-svoa, 0.1 mg | 40 | $407,046 | None |
| Injection of drug into eye | 245 | $152,495 | $116 |
| Injection, ranibizumab, 0.1 mg | 33 | $129,261 | None |
| Imaging of retina | 612 | $92,106 | $41 |
| Short return visit (20+ min) | 397 | $84,861 | $86 |
| Established patient complete exam of visual system | 314 | $35,515 | $112 |
| Established patient problem focused exam of visual system | 195 | $26,047 | $87 |
| Return visit (30+ min) | 123 | $18,836 | $121 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 86 | $15,585 | $169 |
| New patient complete exam of visual system | 94 | $13,135 | $140 |
| New patient visit (45+ min) | 60 | $8,892 | $148 |
| Photography of the retina | 65 | $3,151 | $35 |
| 2d ultrasound scan of eye tissue and structures | 32 | $2,035 | $47 |
| Extended exam of the back part of the eye with retinal drawing | 15 | $313 | $21 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
660 Original Medicare patients in 2024. Average age 79 · Under 65 4% · 85 and older 28% · Women 61% · Also on Medicaid 25% · Health risk score 1.50. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 35% · Chronic kidney disease 29% · Coronary heart disease 24% · Atrial fibrillation 19% · Heart failure 18% · Cancer 16% · COPD 12% · Depression 12% · Dementia 7% · Stroke 7%.
The office billed $7,132,893, Medicare allowed $2,974,130 and paid $2,333,151; for 23,664 services of 32 kinds; $1,862,009 of it was for drugs given in the office and $471,142 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 660 | 23,664 | 79 | 1.50 | $7,132,893 | $2,333,151 |
| 2023 | 588 | 14,851 | 78 | 1.40 | $6,545,004 | $2,245,636 |
| 2022 | 551 | 8,322 | 78 | 1.40 | $5,717,681 | $2,018,967 |
| 2021 | 628 | 9,735 | 78 | 1.43 | $6,364,104 | $2,376,868 |
| 2020 | 597 | 10,228 | 78 | 1.59 | $6,273,139 | $2,352,351 |
| 2019 | 670 | 10,452 | 78 | 1.51 | $5,758,987 | $2,193,566 |
| 2018 | 685 | 8,649 | 77 | 1.52 | $4,204,388 | $1,634,293 |
| 2017 | 608 | 7,553 | 77 | 1.63 | $3,208,058 | $1,302,463 |
| 2016 | 554 | 5,985 | 77 | 1.52 | $1,971,726 | $973,574 |
| 2015 | 528 | 5,964 | 77 | 1.51 | $1,949,751 | $1,023,790 |
| 2014 | 408 | 4,348 | 77 | 1.34 | $1,352,953 | $771,153 |
| 2013 | 583 | 3,053 | 78 | 1.38 | $1,313,511 | $569,852 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Injection, aflibercept, 1 mg | 182 | $1,433,171 | None |
| Injection, ranibizumab, 0.1 mg | 43 | $222,145 | None |
| Injection, faricimab-svoa, 0.1 mg | 23 | $177,090 | None |
| Injection of drug into eye | 230 | $144,099 | $111 |
| Established patient problem focused exam of visual system | 383 | $86,030 | $84 |
| Imaging of retina | 530 | $79,310 | $39 |
| Established patient complete exam of visual system | 225 | $24,694 | $110 |
| New patient complete exam of visual system | 113 | $15,144 | $134 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 78 | $12,094 | $136 |
| Short return visit (20+ min) | 95 | $9,600 | $87 |
| New patient visit (45+ min) | 41 | $6,221 | $152 |
| Compounded drug, not otherwise classified | 16 | $5,470 | None |
| Return visit (30+ min) | 43 | $5,011 | $104 |
| Short return visit | 62 | $3,997 | $56 |
| Photography of the retina | 64 | $2,900 | $34 |
| 2d ultrasound scan of eye tissue and structures | 20 | $1,274 | $47 |
| Extended exam of the back part of the eye with retinal drawing | 11 | $263 | $24 |
2022: 15 services
| Injection, aflibercept, 1 mg | 155 | $1,302,059 | None |
| Injection, ranibizumab, 0.1 mg | 54 | $349,394 | None |
| Injection of drug into eye | 223 | $124,878 | $108 |
| Established patient problem focused exam of visual system | 372 | $89,732 | $82 |
| Imaging of retina | 473 | $67,247 | $38 |
| Established patient complete exam of visual system | 242 | $27,226 | $112 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 66 | $9,858 | $119 |
| New patient complete exam of visual system | 60 | $8,534 | $142 |
| Compounded drug, not otherwise classified | 22 | $5,916 | None |
| Photography of the retina | 97 | $5,138 | $34 |
| New patient visit (45+ min) | 38 | $4,702 | $124 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,309 | $331 |
| Return visit (30+ min) | 23 | $2,460 | $107 |
| 2d ultrasound scan of eye tissue and structures | 23 | $1,429 | $41 |
| Extended exam of the back part of the eye with retinal drawing | 14 | $331 | $24 |
2021: 14 services
| Injection, aflibercept, 1 mg | 138 | $1,319,141 | None |
| Injection, ranibizumab, 0.1 mg | 85 | $630,489 | None |
| Injection of drug into eye | 241 | $144,308 | $111 |
| Established patient problem focused exam of visual system | 314 | $92,549 | $86 |
| Imaging of retina | 538 | $75,669 | $40 |
| Established patient complete exam of visual system | 333 | $45,498 | $104 |
| New patient visit (45+ min) | 132 | $18,637 | $141 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 72 | $10,541 | $121 |
| Compounded drug, not otherwise classified | 29 | $8,046 | None |
| Photocoagulation treatment to prevent detachment of retina | 12 | $5,919 | $493 |
| Photography of the retina | 125 | $5,736 | $36 |
| 2d ultrasound scan of eye tissue and structures | 24 | $2,758 | $49 |
| Extended exam of the back part of the eye with retinal drawing | 35 | $789 | $22 |
| Extended exam of the back part of the eye with optic nerve drawing | 19 | $290 | $15 |
2020: 14 services
| Injection, aflibercept, 1 mg | 111 | $1,175,954 | None |
| Injection, ranibizumab, 0.1 mg | 100 | $727,894 | None |
| Injection of drug into eye | 237 | $126,826 | $96 |
| Established patient problem focused exam of visual system | 279 | $105,801 | $84 |
| Imaging of retina | 509 | $73,463 | $39 |
| Established patient complete exam of visual system | 359 | $57,085 | $106 |
| New patient visit (45+ min) | 144 | $19,635 | $136 |
| Compounded drug, not otherwise classified | 34 | $10,458 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 87 | $10,289 | $105 |
| Photography of the retina | 138 | $7,944 | $42 |
| Destruction of leaking blood vessels of retina using laser | 12 | $6,405 | $320 |
| 2d ultrasound scan of eye tissue and structures | 27 | $2,130 | $52 |
| Extended exam of the back part of the eye with retinal drawing | 58 | $1,474 | $23 |
| Extended exam of the back part of the eye with optic nerve drawing | 51 | $784 | $15 |
2019: 14 services
| Injection, aflibercept, 1 mg | 99 | $885,992 | None |
| Injection, ranibizumab, 0.1 mg | 119 | $837,625 | None |
| Injection of drug into eye | 242 | $121,535 | $96 |
| Established patient problem focused exam of visual system | 323 | $114,559 | $84 |
| Imaging of retina | 558 | $77,012 | $39 |
| Established patient complete exam of visual system | 397 | $64,650 | $105 |
| New patient visit (45+ min) | 164 | $21,227 | $129 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 113 | $11,933 | $93 |
| Compounded drug, not otherwise classified | 56 | $9,699 | None |
| Destruction of leaking blood vessels of retina using laser | 17 | $8,672 | $334 |
| Photography of the retina | 152 | $8,531 | $47 |
| Examination of eye by ophthalmoscope with retinal drawing | 111 | $5,253 | $27 |
| Examination of eye by ophthalmoscope with retinal drawing | 54 | $2,423 | $25 |
| 2d ultrasound scan of eye tissue and structures | 26 | $1,827 | $57 |
2018: 15 services
| Injection, ranibizumab, 0.1 mg | 80 | $652,980 | None |
| Injection, aflibercept, 1 mg | 55 | $557,485 | None |
| Established patient problem focused exam of visual system | 300 | $96,912 | $80 |
| Injection of drug into eye | 198 | $96,727 | $95 |
| Imaging of retina | 564 | $71,053 | $39 |
| Established patient complete exam of visual system | 394 | $61,065 | $110 |
| New patient visit (45+ min) | 192 | $24,659 | $128 |
| Compounded drug, not otherwise classified | 69 | $16,254 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 78 | $6,785 | $85 |
| Destruction of leaking blood vessels of retina using laser | 14 | $5,922 | $312 |
| Photography of the retina | 105 | $5,737 | $52 |
| Examination of eye by ophthalmoscope with retinal drawing | 119 | $5,205 | $26 |
| 2d ultrasound scan of eye tissue and structures | 31 | $3,400 | $74 |
| Examination of eye by ophthalmoscope with retinal drawing | 29 | $1,064 | $24 |
| Imaging of optic nerve | 19 | $490 | $26 |
2017: 15 services
| Injection, ranibizumab, 0.1 mg | 63 | $485,126 | None |
| Injection, aflibercept, 1 mg | 41 | $408,309 | None |
| Established patient problem focused exam of visual system | 322 | $96,439 | $78 |
| Injection of drug into eye | 181 | $87,342 | $95 |
| Imaging of retina | 506 | $63,874 | $38 |
| Established patient complete exam of visual system | 303 | $40,615 | $103 |
| New patient visit (45+ min) | 195 | $26,442 | $136 |
| Compounded drug, not otherwise classified | 84 | $21,347 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 99 | $7,682 | $77 |
| Photography of the retina | 110 | $7,423 | $67 |
| Destruction of leaking blood vessels of retina using laser | 16 | $5,899 | $295 |
| 2d ultrasound scan of eye tissue and structures | 42 | $5,076 | $85 |
| Examination of eye by ophthalmoscope with retinal drawing | 96 | $3,967 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $838 | $22 |
| Imaging of optic nerve | 15 | $476 | $32 |
2016: 14 services
| Injection, ranibizumab, 0.1 mg | 56 | $331,810 | None |
| Injection, aflibercept, 1 mg | 25 | $276,733 | None |
| Established patient problem focused exam of visual system | 308 | $82,505 | $79 |
| Injection of drug into eye | 157 | $62,628 | $92 |
| Imaging of retina | 450 | $57,100 | $42 |
| New patient visit (45+ min) | 226 | $31,108 | $138 |
| Established patient complete exam of visual system | 212 | $25,718 | $99 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 103 | $21,355 | $103 |
| Compounded drug, not otherwise classified | 80 | $15,043 | None |
| Photography of the retina | 116 | $8,733 | $70 |
| 2d ultrasound scan of eye tissue and structures | 33 | $6,488 | $90 |
| Destruction of leaking blood vessels of retina using laser | 16 | $6,120 | $322 |
| Examination of eye by ophthalmoscope with retinal drawing | 94 | $3,679 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 25 | $811 | $24 |
2015: 15 services
| Injection, ranibizumab, 0.1 mg | 60 | $418,130 | None |
| Injection, aflibercept, 1 mg | 22 | $240,990 | None |
| Established patient problem focused exam of visual system | 289 | $66,288 | $81 |
| Injection of drug into eye | 133 | $63,301 | $99 |
| Imaging of retina | 390 | $47,769 | $43 |
| New patient visit (45+ min) | 241 | $35,122 | $146 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 140 | $28,429 | $103 |
| Established patient complete exam of visual system | 205 | $26,033 | $101 |
| Destruction of leaking blood vessels of retina using laser | 11 | $15,011 | $938 |
| Photography of the retina | 155 | $10,749 | $69 |
| Unclassified biologics | 48 | $8,070 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 158 | $7,256 | $26 |
| 2d ultrasound scan of eye tissue and structures | 46 | $7,188 | $91 |
| Examination of eye by ophthalmoscope with retinal drawing | 79 | $2,925 | $23 |
| Compounded Drug, Not Otherwise Classified | 30 | $2,511 | $55 |
2014: 14 services
| Injection, ranibizumab, 0.1 mg | 44 | $362,340 | None |
| Injection, aflibercept, 1 mg | 14 | $127,464 | None |
| Injection of drug into eye | 108 | $47,586 | $95 |
| Established patient complete exam of visual system | 206 | $34,960 | $109 |
| Imaging of retina | 273 | $31,562 | $43 |
| New patient visit (45+ min) | 213 | $29,911 | $140 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 140 | $29,141 | $103 |
| Established patient problem focused exam of visual system | 123 | $14,826 | $81 |
| Destruction of leaking blood vessels of retina using laser | 11 | $12,478 | $960 |
| Photography of the retina | 152 | $11,001 | $70 |
| Unclassified biologics | 56 | $9,080 | None |
| 2d ultrasound scan of eye tissue and structures | 45 | $6,382 | $90 |
| Examination of eye by ophthalmoscope with retinal drawing | 153 | $5,818 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 52 | $1,572 | $23 |
2013: 15 services
| Injection, aflibercept, 1 mg | 38 | $193,746 | None |
| Injection, ranibizumab, 0.1 mg | 45 | $163,838 | None |
| Injection of drug into eye | 119 | $28,736 | $94 |
| Imaging of retina | 381 | $25,359 | $39 |
| Established patient problem focused exam of visual system | 253 | $24,897 | $69 |
| New patient visit (45+ min) | 150 | $22,061 | $147 |
| Established patient complete exam of visual system | 176 | $17,698 | $98 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 72 | $15,034 | $107 |
| Removal of eye fluid (vitreous) between lens and retina | 16 | $14,158 | $885 |
| Photography of the retina | 84 | $5,983 | $70 |
| 2d ultrasound scan of eye tissue and structures | 30 | $4,064 | $90 |
| Unclassified biologics | 36 | $4,042 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 119 | $3,497 | $29 |
| New patient complete exam of visual system | 23 | $2,490 | $108 |
| Examination of eye by ophthalmoscope with retinal drawing | 46 | $1,346 | $27 |
Medicaid work
$597,294 in 2024
Medicaid paid $597,294 for 2,706 billed services this clinician did in 2024, up to 63 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 409 | $392,665 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 647 | $157,839 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,011 | $22,969 |
| Short return visit (20+ min) | 514 | $19,925 |
| Injection, bevacizumab, 10 mg | 32 | $2,109 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 64 | $1,629 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 29 | $157 |
| 2024 | 2,706 | 7 | 63 | $597,294 |
| 2023 | 3,581 | 7 | 59 | $1,049,281 |
| 2022 | 3,694 | 8 | 51 | $1,099,537 |
| 2021 | 3,339 | 8 | 59 | $922,656 |
| 2020 | 2,996 | 7 | 52 | $1,050,746 |
| 2019 | 2,742 | 7 | 46 | $888,497 |
| 2018 | 2,285 | 5 | 44 | $1,158,444 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 619 | $772,583 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 846 | $219,568 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,162 | $27,028 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 786 | $23,396 |
| Injection, bevacizumab, 10 mg | 98 | $3,979 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 44 | $2,601 |
| Short return visit (20+ min) | 26 | $126 |
2022
| Aflibercept injection | 672 | $848,113 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 852 | $196,982 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 882 | $23,826 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 989 | $20,599 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 170 | $6,613 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 39 | $1,724 |
| Injection, bevacizumab, 10 mg | 66 | $1,017 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 24 | $663 |
2021
| Aflibercept injection | 583 | $706,876 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 798 | $169,389 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 799 | $22,444 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 993 | $20,062 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 37 | $1,975 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 71 | $1,151 |
| Injection, bevacizumab, 10 mg | 46 | $641 |
| New patient visit (45+ min) | 12 | $118 |
2020
| Aflibercept injection | 490 | $805,748 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 760 | $200,732 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 742 | $22,704 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 871 | $19,946 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 102 | $1,244 |
| Injection, bevacizumab, 10 mg | 15 | $235 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 16 | $137 |
2019
| Aflibercept injection | 316 | $656,686 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 702 | $182,079 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 850 | $25,342 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 750 | $22,896 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 92 | $1,054 |
| Injection, bevacizumab, 10 mg | 18 | $293 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 14 | $148 |
2018
| Aflibercept injection | 282 | $936,229 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 561 | $175,743 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 760 | $24,130 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 669 | $22,205 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $136 |
Drugs they prescribed that Part D paid
$8,660
Pharmacies billed $8,660 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 217) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
127 generic and 90 brand-name prescriptions · $8,660 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 63 | $2,435 | $39 |
| Ketorolac Tromethamine | 34 | $922 | $27 |
| Diclofenac | 31 | $296 | $10 |
| Neomycin-Polymyxin-Dexameth | 25 | $265 | $11 |
| Brimonidine | 16 | $134 | $8 |
Year by year
| 2024 | 217 | 64 | 0% (0) | 41% | $8,660 |
| 2023 | 165 | 48 | 0% (0) | 32% | $7,588 |
| 2022 | 166 | 51 | 0% (0) | 31% | $7,527 |
| 2021 | 172 | 56 | 0% (0) | 38% | $7,799 |
| 2020 | 241 | 65 | None | 55% | $26,163 |
| 2019 | 261 | 66 | None | 46% | $17,658 |
| 2018 | 194 | 57 | None | 44% | $13,013 |
| 2017 | 189 | 63 | 6% (12) | 47% | $12,363 |
| 2016 | 180 | 68 | 8% (15) | 44% | $12,494 |
| 2015 | 185 | 60 | None | 49% | $13,270 |
| 2014 | 132 | 56 | 8% (11) | 40% | $8,642 |
| 2013 | 205 | 60 | None | 58% | $15,684 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Prednisolone Acetate | 30 | $1,160 | $39 |
| Ketorolac Tromethamine | 44 | $809 | $18 |
| Neomycin-Polymyxin-Dexameth | 33 | $530 | $16 |
| Brimonidine | 12 | $117 | $10 |
2022: 4 drugs
| Prednisolone Acetate | 37 | $1,665 | $45 |
| Neomycin-Polymyxin-Dexameth | 41 | $593 | $14 |
| Ketorolac Tromethamine | 35 | $511 | $15 |
| Latanoprost | 14 | $436 | $31 |
2021: 5 drugs
| Prednisolone Acetate | 37 | $1,587 | $43 |
| Neomycin-Polymyxin-Dexameth | 45 | $792 | $18 |
| Timolol Maleate | 17 | $398 | $23 |
| Ketorolac Tromethamine | 21 | $286 | $14 |
| Latanoprost | 15 | $270 | $18 |
2020: 8 drugs
| Azopt | 23 | $7,467 | $325 |
| Prolensa | 16 | $4,444 | $278 |
| Combigan | 11 | $3,327 | $302 |
| Prednisolone Acetate | 54 | $1,889 | $35 |
| Ketorolac Tromethamine | 29 | $620 | $21 |
| Neomycin-Polymyxin-Dexameth | 24 | $404 | $17 |
| Brimonidine | 12 | $309 | $26 |
| Timolol Maleate | 15 | $179 | $12 |
2019: 7 drugs
| Prolensa | 11 | $2,945 | $268 |
| Simbrinza | 15 | $2,531 | $169 |
| Prednisolone Acetate | 61 | $2,388 | $39 |
| Acetazolamide Er | 16 | $667 | $42 |
| Brimonidine | 11 | $560 | $51 |
| Ketorolac Tromethamine | 31 | $533 | $17 |
| Neomycin-Polymyxin-Dexameth | 29 | $434 | $15 |
2018: 5 drugs
| Simbrinza | 11 | $1,755 | $160 |
| Prednisolone Acetate | 39 | $1,515 | $39 |
| Bromfenac | 12 | $771 | $64 |
| Neomycin-Polymyxin-Dexameth | 31 | $429 | $14 |
| Ketorolac Tromethamine | 22 | $327 | $15 |
2017: 4 drugs
| Prednisolone Acetate | 42 | $1,906 | $45 |
| Neomycin-Polymyxin-Dexameth | 60 | $934 | $16 |
| Ketorolac Tromethamine | 17 | $311 | $18 |
| Hydrocodone-Acetaminophen | 12 | $49 | $4 |
2016: 5 drugs
| Nevanac | 13 | $2,946 | $227 |
| Durezol | 13 | $1,988 | $153 |
| Prednisolone Acetate | 29 | $1,469 | $51 |
| Neomycin-Polymyxin-Dexameth | 64 | $1,030 | $16 |
| Hydrocodone-Acetaminophen | 14 | $113 | $8 |
2015: 2 drugs
| Prednisolone Acetate | 44 | $2,353 | $53 |
| Neomycin-Polymyxin-Dexameth | 56 | $974 | $17 |
2014: 3 drugs
| Acetazolamide | 15 | $2,093 | $140 |
| Prednisolone Acetate | 13 | $780 | $60 |
| Neomycin-Polymyxin-Dexameth | 32 | $532 | $17 |
2013: 5 drugs
| Travatan Z | 18 | $2,850 | $158 |
| Combigan | 18 | $2,490 | $138 |
| Alphagan P | 16 | $1,408 | $88 |
| Prednisolone Acetate | 25 | $316 | $13 |
| Pantoprazole | 13 | $97 | $7 |
Money from drug and device companies
$134 in 2025
| 2025 | 1 | 1 | None | $134 |
| 2024 | 3 | 3 | None | $89 |
| 2023 | 3 | 5 | None | $261 |
| 2022 | 2 | 4 | None | $179 |
| 2021 | 1 | 2 | None | $145 |
| 2020 | 1 | 1 | None | $22 |
| 2019 | 5 | 9 | $12,072 | $12,790 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Kyphon Express II Kyphopak Tray | $134 | 1 payment
|
See the published payment
| Medtronic | Meals · 2025-10-29 | Kyphon Express II Kyphopak Tray | $134 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $89
| Genentech USA | Vabysmo | $30 | 1 payment
|
| Astellas Pharma US | Izervay | $30 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $29 | 1 payment
|
2023: $261
| Genentech USA | Vabysmo | $175 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $62 | 2 payments
|
| DePuy Synthes Sales | Vivigen Mis Delivery System | $24 | 1 payment
|
2022: $179
| Genentech | Susvimo | $135 | 1 payment
|
| Globus Medical | Creo | $44 | 2 payments
|
2021: $145
| Genentech USA | Lucentis | $145 | 2 payments
|
2020: $22
| Genentech USA | Lucentis | $22 | 1 payment
|
2019: $12,790
| F. Hoffmann-La Roche AG | Lucentis | $12,072 | 3 payments
|
| Allergan | None | $417 | 1 payment
|
| Genentech | Non-Covered Product | $108 | 2 payments
|
| Hoffmann-La Roche | Non-Covered Product | $107 | 1 payment
|
| Genentech USA | Lucentis | $86 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · Lucentis Dosing Retreatment · 2020 | This clinician | $2,812 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538295720
- Licence
- CA A91494California A91494: Current · expires 2028-06-30
- Trained
- University of Washington School of Medicine, 2003
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1655 Greenfield Ave, #23, Los Angeles, CA, 90025
- NPI first listed
- 2007-02-24
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.